Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Lytix Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Lytix Biopharma şirketinin toplam hissedar öz sermayesi NOK59.2M ve toplam borcu NOK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NOK77.7M ve NOK18.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NOK 0

Borç

Faiz karşılama oranı	n/a
Nakit	NOK 60.18m
Eşitlik	NOK 59.22m
Toplam yükümlülükler	NOK 18.44m
Toplam varlıklar	NOK 77.67m

Son finansal sağlık güncellemeleri

Recent updates

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Aug 31

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Mar 02

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Oct 04

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Jun 21

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

Jan 11

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Jul 16

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Jan 25

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Sep 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LYTIX 'nin kısa vadeli varlıkları ( NOK74.6M ) kısa vadeli yükümlülüklerini ( NOK16.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: LYTIX şirketinin kısa vadeli varlıkları ( NOK74.6M ) uzun vadeli yükümlülüklerini ( NOK2.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LYTIX borçsuzdur.

Borcun Azaltılması: LYTIX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LYTIX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: LYTIX un, serbest nakit akışı her yıl % 9.1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Lytix Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Recent updates

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

New major risk - Share price stability

New minor risk - Shareholder dilution

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer (Melanoma) Representing A Significant Commercial Opportunity

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Full year 2023 earnings released

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma AS to Report Q4, 2023 Results on Feb 15, 2024

Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology

Third quarter 2023 earnings released

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial

Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Full year 2022 earnings released

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

Lytix Biopharma AS to Report Fiscal Year 2022 Results on Mar 30, 2023

Third quarter 2022 earnings released

High number of new and inexperienced directors

Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries

Lytix Biopharma AS Presents Compelling Data in Collaboration with Research Groups At National Cancer Institute and Weill Cornell Medicine, USA

Lytix Biopharma AS Announces Approval to Expand the ATLAS-IT-05 Study to Europe

Lytix Biopharma AS Appoints Stephen Worsley as Chief Business Officer

Co-Founder & CEO recently bought kr100k worth of stock

Lytix Biopharma AS Announces Data from Its Atlas-It-04 Trial in Patients with Progressive Metastatic Soft Tissue Sarcoma

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma as Announces That LTX-315 with Adoptive Cell Therapy Has Been Shown to Generate Tumor-Specific T Cells and Stabilize the Disease in Patients with Metastatic Soft Tissue Sarcoma (STS)

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Lytix Biopharma announces Grant of 3 Million NOK from Oslo Regional Research Fund

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Third quarter 2021 earnings: Revenues in line with analyst expectations

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Lytix Biopharma Initiates Phase II Combination Study in the US with LTX-315 and Pembrolizumab in Patients with Solid Tumors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin